Health News

Dr Reddy’s reduces price of cardiovascular drug Cidmus, Health News, ET HealthWorld

Hyderabad: Dr. Reddy’s Laboratories Ltd. ,Dr Reddy’s) announced a significant price reduction of its cardiovascular drugs Sidmus, It is a pharmaceutical composition containing a combination of sacubitril and valsartan, indicated for heart failure patients with reduced ejection fraction.

Dr Reddy’s Cidmus tablets are available in three strengths: 50 mg, 100 mg, and 200 mg, to be taken twice a day. Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs. 78.32), Rs 49 for 100 mg (down from Rs. 83.86), and Rs 79 for 200 mg (down from Rs. 96.71) per tablet.

According to Dr Reddy’s, the product will be manufactured in-house. The Active Pharmaceutical Ingredients ,API) of Cidmus is manufactured at a USFDA-approved facility. Dr Reddy’s Cidmus has a co-crystal formulation that enhances the bioavailability, solubility, and physical and chemical properties of the drug.

There is a growing incidence of chronic diseases in India, and heart failure is one of them. It is estimated that India has between 8 to 10 million heart failure patients. Dr Reddy’s acquired the cardiovascular brand Cidmus from Novartis AG in 2022 for the India market.

Estimates by the company suggest Cidmus has reached over one lakh patients in India, with a market share of 32 percent. The company claims this price reduction will further widen access to this trusted and established brand in keeping with its purpose of ‘Good Health Can’t Wait’ and Environment, Social, and Governance (ESG) goals of access, affordability, and innovation.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button